Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?
Sevindik, Ömür Gökmen
Özsan, Hayri Güner
Özcan, Mehmet Ali
MetadataShow full item record
CitationSolmaz, Ş., Uzun, Ö., Acar, C., Sevindik, Ö. G., Pişkin, Ö., Özsan, H. G. ... Alacacıoğlu, İ. (2018). Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma? Journal of Laboratory Physicians, 10(4), 363-369. https://dx.doi.org/10.4103/JLP.JLP_36_18
BACKGROUND: Recent reports showed neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. MATERIALS AND METHODS: We retrospectively examined the PLR, NLR, and MLR in a cohort of 186 newly diagnosed multiple myeloma (MM) patients. This study investigated the prognostic relevance of NLR, PLR, and MLR in MM patients. NLR, PLR, and MLR were calculated from whole blood counts before therapy. The Kaplan-Meier curves and multivariate Cox models were used for the evaluation of survival. RESULTS: Applying cutoff of 1.9 (NLR), 120.00 (PLR), and 0.27 (MLR), decreased PLR showed a negative impact on the outcome. Decreased PLR is an independent predictor for PFS and OS. There were no significant differences in median survival between the high and low NLR (P = 0.80) and MLR (P= 0.87) groups. CONCLUSIONS: In this study, thrombocytopenia and low PLR are associated with poor survival in MM patients does this P value apply to thrombocytopenia or low PLR and may serve as the cost-effective prognostic biomarker.